1ST Biotherapeutics joins MJFF LRRK2 gene-targeting program

1ST Biotherapeutics said it joined an initiative led by the Michael J. Fox Foundation (MJFF) aimed at advancing therapies that target the LRRK2 gene, a key genetic contributor to Parkinson’s disease. The initiative, MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, brings together biotech companies and academic research…

Potential Therapy FB-101 Well-tolerated in Healthy Volunteers

FB-101, an experimental oral therapy that 1ST Biotherapeutics is developing as a treatment for Parkinson’s disease, was well-tolerated in the first part of a Phase 1 clinical trial in healthy volunteers, the company announced. In the trial of (NCT04165837), which is being conducted in Baltimore,  24 adults…